We are live on ! Find out more
Commodore Capital

Commodore Capital Portfolio holdings

AUM $1.29B Turnover 37.21%
1-Year Est. Return 224.34%
 

Commodore Capital runs funds that back drug developers, from early-stage public companies to late-stage private ones. It aims to fill a gap it sees between traditional venture capital and public market funds. Its thesis is that small biopharma companies, not large drugmakers, drive much of the innovation in areas like genetic medicines and cell therapies. Michael Kramarz and Egen Atkinson, both medical doctors with MBAs, are its managing partners. They indirectly own a majority of the firm, which began operating in 2019. The funds are open to institutions, pension plans, endowments and high net worth individuals.

This Fund
S&P 500
This Quarter Est. Return
+48.36%
1 Year Est. Return
+224.34%
3 Year Est. Return
+1,776.41%
5 Year Est. Return
+7,447.99%
10 Year Est. Return
–
AUM
$184M
AUM Growth
–
Cap. Flow
+$164M
Cap. Flow %
89.08%
Top 10 Hldgs %
54.84%
Holding
28
New
28
Increased
–
Reduced
–
Closed
–
Avg Time Held
0 years
Top 10 Avg Time Held
0 years
Top 20 Avg Time Held
0 years

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 97.36%
2 Financials 1.51%
3 Industrials 1.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
CCCC icon
1
C4 Therapeutics
CCCC
$348M
$15.9M 8.67%
+481,094
New +$14M
2020 Q4
0 quarters
TRIL
2
DELISTED
Trillium Therapeutics
TRIL
$12.5M 6.82%
+852,871
New +$12.3M
2020 Q4
0 quarters
CNST
3
DELISTED
Constellation Pharmaceuticals
CNST
$12.2M 6.63%
+423,708
New +$10.7M
2020 Q4
0 quarters
FPRX
4
DELISTED
Five Prime Therapeutics
FPRX
$9.05M 4.92%
+532,000
New +$6.67M
2020 Q4
0 quarters
KRON icon
5
DELISTED
Kronos Bio
KRON
$8.93M 4.85%
+298,839
New +$9.38M
2020 Q4
0 quarters
ISEE
6
DELISTED
IVERIC bio
ISEE
$8.8M 4.79%
+1,274,261
New +$8.15M
2020 Q4
0 quarters
ACRS icon
7
Aclaris Therapeutics
ACRS
$571M
$8.65M 4.7%
+1,336,275
New +$5.64M
2020 Q4
0 quarters
COGT icon
8
Cogent Biosciences
COGT
$4.77B
$8.54M 4.64%
+760,025
New +$8.35M
2020 Q4
0 quarters
CBAY icon
9
DELISTED
Cymabay Therapeutics
CBAY
$8.53M 4.64%
+1,486,107
New +$11.2M
2020 Q4
0 quarters
PMVP icon
10
PMV Pharmaceuticals
PMVP
$89.9M
$7.69M 4.18%
+125,000
New +$4.9M
2020 Q4
0 quarters
SNDX icon
11
Syndax Pharmaceuticals
SNDX
$822M
$7.35M 3.99%
+330,315
New +$6.85M
2020 Q4
0 quarters
XENE icon
12
Xenon Pharmaceuticals
XENE
$3.86B
$7.19M 3.91%
+467,368
New +$5.47M
2020 Q4
0 quarters
PTGX icon
13
Protagonist Therapeutics
PTGX
$8.15B
$7.01M 3.81%
+347,500
New +$7.48M
2020 Q4
0 quarters
MREO icon
14
Mereo BioPharma
MREO
$48.7M
$6.64M 3.61%
+1,854,278
New +$4.64M
2020 Q4
0 quarters
CLDX icon
15
Celldex Therapeutics
CLDX
$2.25B
$6.24M 3.4%
+356,431
New +$6.41M
2020 Q4
0 quarters
VTGN icon
16
VistaGen Therapeutics
VTGN
$8.18M
$6.11M 3.32%
+105,000
New +$2.68M
2020 Q4
0 quarters
RLMD icon
17
Relmada Therapeutics
RLMD
$385M
$5.73M 3.11%
+178,565
New +$6.14M
2020 Q4
0 quarters
SPRY icon
18
ARS Pharmaceuticals
SPRY
$361M
$4.5M 2.45%
+97,143
New +$3.24M
2020 Q4
0 quarters
KURA icon
19
Kura Oncology
KURA
$651M
$4.36M 2.37%
+133,503
New +$4.69M
2020 Q4
0 quarters
SURF
20
DELISTED
Surface Oncology
SURF
$4.32M 2.35%
+467,796
New +$4.07M
2020 Q4
0 quarters
GNCA
21
DELISTED
Genocea Biosciences
GNCA
$4.27M 2.32%
+1,765,901
New +$4.02M
2020 Q4
0 quarters
MRSN icon
22
DELISTED
Mersana Therapeutics
MRSN
$4.23M 2.3%
+6,353
New +$3.53M
2020 Q4
0 quarters
IMVT icon
23
Immunovant
IMVT
$6.89B
$3.87M 2.1%
+83,782
New +$3.87M
2020 Q4
0 quarters
IVA icon
24
Inventiva
IVA
$794M
$3.35M 1.82%
+231,000
New +$2.99M
2020 Q4
0 quarters
BLSA
25
DELISTED
BCLS Acquisition Corp
BLSA
$2.78M 1.51%
+250,000
New +$2.68M
2020 Q4
0 quarters

Similar funds

Commodore Capital's Q4 2020 Portfolio in Review

Q4 2020 is the first quarter with a 13F filing on record for Commodore Capital, which disclosed 28 positions worth $184M. Its ten largest holdings account for 55% of the portfolio.

Its largest position is C4 Therapeutics: 481,094 shares worth $15.9M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, followed by Financials and Industrials.

  • Commodore Capital's largest Q4 2020 buy was C4 Therapeutics: 481,094 shares worth $15.9M.
  • Commodore Capital's ten largest holdings make up 55% of its $184M portfolio in Q4 2020.
  • Commodore Capital disclosed 28 positions in Q4 2020, its first 13F filing on record.

Based on Commodore Capital's 13F filing for Q4 2020, filed 16 Feb 2021.